ANDA 78225, held by Zydus Pharmaceuticals (USA). Tamsulosin Hydrochloride.
As of Nov 21, 2026, ANDA 78225 (Tamsulosin Hydrochloride), held by Zydus Pharmaceuticals (USA), was first approved by FDA on Apr 27, 2010, with 5 approved supplements and 0 published complete response letters.
Tamsulosin hydrochloride capsules are an alpha 1 adrenoceptor antagonist indicated for treatment of the signs and symptoms of benign prostatic hyperplasia Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension Tamsulosin hydrochloride capsules, USP are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 27, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tamsulosin Hydrochloride0.4MG · capsule;oral | Tamsulosin Hydrochloride | Rx |
| Sep 9, 2019 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 22, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 22, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 29, 2011 | Supplement 4Labeling | Approved | None posted |
| Oct 2, 2010 | Supplement 1Manufacturing | Approved | None posted |
| Apr 27, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters